Trials / Not Yet Recruiting
Not Yet RecruitingNCT06697366
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Liposomal Irinotecan in Combination with Sintilimab in Second-Line Treatment of Progressive Gastric Cancer, a Single-Arm, Single-Center, Open-Label, Phase II Clinical Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the efficacy and safety of irinotecan liposome injection in combination with Sintilimab in the second-line treatment of progressive gastric cancer
Detailed description
This is a single-center, open, single-arm clinical study to evaluate the efficacy and safety of irinotecan liposome injection in combination with Sintilimab in the second-line treatment of progressed gastric cancer, and to provide more clinical treatment options for gastric cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan liposome injection Ⅱ | 56.6 mg/m2，Q3W |
| DRUG | Sintilimab | 200mg，Q3W |
Timeline
- Start date
- 2024-11-20
- Primary completion
- 2026-05-20
- Completion
- 2026-11-20
- First posted
- 2024-11-20
- Last updated
- 2024-11-20
Source: ClinicalTrials.gov record NCT06697366. Inclusion in this directory is not an endorsement.